Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 13/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.41 |
| ▸ | MAP2K6 | P52564 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.41 |
| ▸ | NEK10 | Q6ZWH5 | 1/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.41 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | CLK2 | P49760 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4606841 | 0.85 | LRRK2 (0.41) | LRRK2LCKMAP2K3MAP2K6BTK | |
| SCHEMBL4930365 | 0.85 | LRRK2 (0.47) | LRRK2LCKMAP2K3MAP2K6BTK | |
| SCHEMBL14034412 | 0.84 | LRRK2 (0.40) | LRRK2LCKMAP2K3MAP2K6BTK | |
| SCHEMBL20839036 | 0.80 | LCK (0.46) | LRRK2LCKMAP2K3MAP2K6BTK | |
| SCHEMBL19384268 | 0.78 | LCK (0.44) | LRRK2LCKMAP2K3MAP2K6BTK | |
| SCHEMBL4607280 | 0.78 | LCK (0.44) | LRRK2LCKMAP2K3MAP2K6BTK | |
| SCHEMBL4607457 | 0.76 | SLC2A1 (0.49) | LCKBTKSLC2A1KDM4E | |
| SCHEMBL4608167 | 0.76 | LRRK2 (0.41) | LRRK2 | |
| SCHEMBL4607554 | 0.75 | SLC2A1 (0.38) | SLC2A1 | |
| SCHEMBL4609219 | 0.75 | PDE4B (0.49) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280911-A1 | Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| US-20080280911-A1 | Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| US-20080280911-A1 | Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| EP-1945616-A1 | CINNOLINE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE TYPE IV (PDE4) | GLAXO GROUP LIMITED (GB) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007045861-A1 | CINNOLINE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE TYPE IV (PDE4) | GLAXO GROUP LIMITED (GB) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007045861-A1 | CINNOLINE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE TYPE IV (PDE4) | GLAXO GROUP LIMITED (GB) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280911-A1 | Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) | PDE4A, PDE4B, PDE3B | LRRK2 2855/4885LCK 4551/4885MAP2K3 2385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.